인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Abstract Background β2-microglobulin (β2-MG) is recognized as a surrogate marker for putative middle-molecule uremic toxins. Its clearance by peritoneal dialysis (PD) is limited but increases significantly when hemodialysis (HD) is added. In Japan, combined PD and HD therapy is frequently introduced when patients undergoing PD experience a decline in residual renal function. However, even with combined therapy, persistently elevated serum β2-MG levels often lead to a transition to thrice-weekly HD. This report describes a case in which elevated β2-MG levels were attributed to overproduction rather than insufficient solute removal in a patient receiving combined PD and HD therapy. Case presentation The patient, a 76-year-old woman with end-stage renal disease due to immunoglobulin (Ig)A nephropathy, initiated PD 12 years prior and started weekly HD 2 years prior, following a reduction in residual renal function. Despite the addition of HD, serum β2-MG levels remained elevated; however, peritoneal function was preserved, and PD was continued. The patient later experienced a spontaneous fracture of the right distal radius, leading to a diagnosis of multiple myeloma, which was identified as the underlying cause of the elevated β2-MG. Following initiation of chemotherapy, β2-MG levels declined markedly. Conclusions In prevalent patients with PD, serum β2-MG alone has limited prognostic value. This case highlights the need for a comprehensive assessment when interpreting elevated β2-MG levels and supports individualized treatment decisions rather than reliance on a single biomarker.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
